 Hans Dooms
Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Interleukin-7 | 6 | 2026 | 28 | 2.120 |
Why?
| | T-Lymphocytes, Regulatory | 8 | 2026 | 409 | 1.700 |
Why?
| | Immunologic Memory | 8 | 2021 | 368 | 1.550 |
Why?
| | Interleukin-2 | 12 | 2012 | 440 | 1.360 |
Why?
| | CD4-Positive T-Lymphocytes | 11 | 2021 | 1140 | 1.180 |
Why?
| | Autoimmunity | 4 | 2026 | 933 | 1.040 |
Why?
| | Interleukin-7 | 6 | 2017 | 66 | 1.020 |
Why?
| | Forkhead Transcription Factors | 4 | 2026 | 207 | 1.020 |
Why?
| | Diabetes Mellitus, Type 1 | 7 | 2026 | 3922 | 0.980 |
Why?
| | Adoptive Transfer | 3 | 2021 | 200 | 0.780 |
Why?
| | STAT5 Transcription Factor | 2 | 2021 | 50 | 0.710 |
Why?
| | Lymphocyte Activation | 13 | 2021 | 1132 | 0.710 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 2 | 2018 | 28 | 0.670 |
Why?
| | Antibodies, Monoclonal | 3 | 2019 | 1505 | 0.650 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2018 | 265 | 0.650 |
Why?
| | Interleukin-7 Receptor alpha Subunit | 1 | 2019 | 11 | 0.590 |
Why?
| | T-Lymphocytes | 5 | 2013 | 1996 | 0.560 |
Why?
| | Adjuvants, Immunologic | 3 | 2007 | 243 | 0.530 |
Why?
| | Mice, Inbred NOD | 4 | 2026 | 613 | 0.530 |
Why?
| | Cytokines | 4 | 2023 | 2067 | 0.510 |
Why?
| | Scleroderma, Systemic | 1 | 2018 | 123 | 0.500 |
Why?
| | Lymphocytes | 2 | 2018 | 376 | 0.490 |
Why?
| | Receptors, Immunologic | 1 | 2018 | 208 | 0.490 |
Why?
| | Autoantigens | 2 | 2019 | 427 | 0.480 |
Why?
| | Immunotherapy | 2 | 2019 | 666 | 0.460 |
Why?
| | Interleukin-15 | 4 | 2012 | 95 | 0.420 |
Why?
| | Islets of Langerhans | 1 | 2021 | 846 | 0.420 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2017 | 919 | 0.400 |
Why?
| | Mice | 25 | 2026 | 18329 | 0.380 |
Why?
| | T-Lymphocyte Subsets | 5 | 2018 | 418 | 0.350 |
Why?
| | Animals | 29 | 2026 | 38030 | 0.320 |
Why?
| | Autoimmune Diseases | 1 | 2013 | 468 | 0.290 |
Why?
| | Signal Transduction | 7 | 2021 | 5216 | 0.290 |
Why?
| | Pneumonia, Pneumococcal | 2 | 2020 | 47 | 0.270 |
Why?
| | Th1 Cells | 4 | 2023 | 139 | 0.270 |
Why?
| | Mice, Knockout | 8 | 2026 | 3124 | 0.260 |
Why?
| | Cell Differentiation | 6 | 2020 | 2046 | 0.240 |
Why?
| | Antibodies, Blocking | 2 | 2018 | 37 | 0.230 |
Why?
| | Th2 Cells | 3 | 2023 | 175 | 0.230 |
Why?
| | Leukocytes, Mononuclear | 2 | 2018 | 574 | 0.220 |
Why?
| | Immune Tolerance | 4 | 2013 | 385 | 0.210 |
Why?
| | Disease Models, Animal | 5 | 2020 | 4560 | 0.200 |
Why?
| | Immunity | 2 | 2017 | 140 | 0.200 |
Why?
| | Cell Proliferation | 5 | 2019 | 2507 | 0.200 |
Why?
| | Helminthiasis | 1 | 2023 | 11 | 0.190 |
Why?
| | Apoptosis | 4 | 2002 | 2440 | 0.190 |
Why?
| | Cells, Cultured | 6 | 2017 | 4148 | 0.180 |
Why?
| | Cell Lineage | 1 | 2002 | 377 | 0.160 |
Why?
| | Interferon-gamma | 3 | 2012 | 784 | 0.140 |
Why?
| | Mice, Inbred BALB C | 6 | 2010 | 1261 | 0.140 |
Why?
| | Immunization, Secondary | 1 | 1998 | 92 | 0.140 |
Why?
| | Antigens, Viral | 1 | 1998 | 182 | 0.130 |
Why?
| | Immunity, Heterologous | 1 | 2017 | 2 | 0.130 |
Why?
| | Mice, Transgenic | 6 | 2012 | 2188 | 0.130 |
Why?
| | Immunization | 1 | 2019 | 375 | 0.130 |
Why?
| | Macrophages, Alveolar | 1 | 2020 | 373 | 0.120 |
Why?
| | Female | 11 | 2026 | 78844 | 0.120 |
Why?
| | Receptors, Interleukin-2 | 2 | 2008 | 64 | 0.120 |
Why?
| | Homeostasis | 2 | 2013 | 642 | 0.120 |
Why?
| | Cell Survival | 2 | 2013 | 1100 | 0.120 |
Why?
| | Antigens, CD | 2 | 2017 | 558 | 0.120 |
Why?
| | Streptococcus pneumoniae | 1 | 2017 | 184 | 0.110 |
Why?
| | CD40 Ligand | 2 | 2012 | 40 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2012 | 673 | 0.110 |
Why?
| | Lipid Metabolism | 1 | 2017 | 529 | 0.100 |
Why?
| | Mitochondria | 2 | 2017 | 992 | 0.100 |
Why?
| | 4-1BB Ligand | 1 | 2012 | 7 | 0.100 |
Why?
| | Isoantigens | 1 | 2012 | 17 | 0.090 |
Why?
| | Phenotype | 1 | 2021 | 3155 | 0.090 |
Why?
| | Antigens, Differentiation | 1 | 2012 | 76 | 0.090 |
Why?
| | Gene Expression Regulation | 4 | 2023 | 2597 | 0.090 |
Why?
| | Anemia, Hemolytic, Autoimmune | 2 | 2010 | 14 | 0.090 |
Why?
| | Humans | 14 | 2021 | 145474 | 0.080 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 2 | 2010 | 82 | 0.080 |
Why?
| | Energy Metabolism | 1 | 2017 | 935 | 0.080 |
Why?
| | Polymorphism, Genetic | 1 | 2013 | 614 | 0.080 |
Why?
| | Vaccination | 1 | 2019 | 1426 | 0.080 |
Why?
| | CD28 Antigens | 2 | 2007 | 59 | 0.080 |
Why?
| | Mice, Inbred C57BL | 7 | 2017 | 5983 | 0.070 |
Why?
| | Cell Death | 2 | 2002 | 382 | 0.070 |
Why?
| | Lung | 2 | 2020 | 4106 | 0.070 |
Why?
| | Cell Separation | 2 | 2012 | 305 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2378 | 0.050 |
Why?
| | Mitomycin | 1 | 2004 | 32 | 0.050 |
Why?
| | Oxygen Consumption | 2 | 2017 | 718 | 0.050 |
Why?
| | Ovalbumin | 1 | 2004 | 194 | 0.050 |
Why?
| | CD3 Complex | 2 | 2002 | 112 | 0.050 |
Why?
| | Immunity, Innate | 2 | 2020 | 835 | 0.050 |
Why?
| | Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2002 | 9 | 0.050 |
Why?
| | Self Tolerance | 1 | 2002 | 26 | 0.050 |
Why?
| | Cell Division | 1 | 2004 | 756 | 0.050 |
Why?
| | Clone Cells | 2 | 1998 | 263 | 0.040 |
Why?
| | Immunophenotyping | 2 | 1998 | 319 | 0.040 |
Why?
| | Peptide Fragments | 1 | 2004 | 693 | 0.040 |
Why?
| | Cytochrome c Group | 1 | 2000 | 43 | 0.040 |
Why?
| | Phosphatidylserines | 1 | 2000 | 62 | 0.040 |
Why?
| | Antigens, Tumor-Associated, Carbohydrate | 1 | 1998 | 8 | 0.040 |
Why?
| | Chondroitin Sulfate Proteoglycans | 1 | 1998 | 10 | 0.040 |
Why?
| | Neoplasms, Experimental | 1 | 1999 | 167 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2020 | 147 | 0.040 |
Why?
| | Interphase | 1 | 1998 | 38 | 0.040 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 1998 | 104 | 0.030 |
Why?
| | Hemagglutinin Glycoproteins, Influenza Virus | 1 | 1998 | 29 | 0.030 |
Why?
| | Lymphocyte Count | 1 | 1998 | 164 | 0.030 |
Why?
| | Gene Expression | 1 | 2023 | 1476 | 0.030 |
Why?
| | Oleic Acid | 1 | 2017 | 40 | 0.030 |
Why?
| | Aged | 1 | 2018 | 26153 | 0.030 |
Why?
| | Lipid Peroxidation | 1 | 2017 | 167 | 0.030 |
Why?
| | Serogroup | 1 | 2017 | 45 | 0.030 |
Why?
| | Inflammation | 1 | 2008 | 2878 | 0.030 |
Why?
| | Bacterial Load | 1 | 2017 | 67 | 0.030 |
Why?
| | Extracellular Space | 1 | 2017 | 117 | 0.030 |
Why?
| | Interleukin-17 | 1 | 2017 | 120 | 0.030 |
Why?
| | DNA Replication | 1 | 1998 | 249 | 0.030 |
Why?
| | Cellular Microenvironment | 1 | 2017 | 93 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2017 | 1217 | 0.030 |
Why?
| | Virulence | 1 | 2017 | 278 | 0.030 |
Why?
| | Middle Aged | 1 | 2018 | 36215 | 0.030 |
Why?
| | Adenosine Triphosphate | 1 | 2017 | 500 | 0.030 |
Why?
| | Male | 2 | 2018 | 72842 | 0.030 |
Why?
| | Transcription Factors | 1 | 2023 | 1734 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2012 | 1162 | 0.030 |
Why?
| | Adult | 1 | 2018 | 40777 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2017 | 1067 | 0.030 |
Why?
| | Proteins | 1 | 1999 | 1023 | 0.020 |
Why?
| | Metabolome | 1 | 2017 | 388 | 0.020 |
Why?
| | Interleukin-15 Receptor alpha Subunit | 1 | 2012 | 1 | 0.020 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2012 | 23 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 1998 | 1443 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2012 | 170 | 0.020 |
Why?
| | Fibroblasts | 1 | 2017 | 1025 | 0.020 |
Why?
| | RNA, Messenger | 1 | 1999 | 2803 | 0.020 |
Why?
| | Cyclosporine | 1 | 2012 | 256 | 0.020 |
Why?
| | Metabolomics | 1 | 2017 | 732 | 0.020 |
Why?
| | Bcl-2-Like Protein 11 | 1 | 2010 | 37 | 0.020 |
Why?
| | Macrophages | 1 | 1998 | 1507 | 0.020 |
Why?
| | Graft vs Host Disease | 1 | 2012 | 279 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2010 | 247 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2010 | 187 | 0.020 |
Why?
| | Resting Phase, Cell Cycle | 1 | 2009 | 16 | 0.020 |
Why?
| | Vaccinia virus | 1 | 2009 | 35 | 0.020 |
Why?
| | Gene Deletion | 1 | 2010 | 391 | 0.020 |
Why?
| | Algorithms | 1 | 2017 | 1845 | 0.020 |
Why?
| | Tumor Cells, Cultured | 2 | 1999 | 886 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2010 | 624 | 0.020 |
Why?
| | Skin | 1 | 2011 | 753 | 0.010 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2007 | 376 | 0.010 |
Why?
| | Inflammation Mediators | 1 | 2008 | 506 | 0.010 |
Why?
| | Biomarkers | 1 | 2017 | 4295 | 0.010 |
Why?
| | Antibodies | 1 | 2007 | 397 | 0.010 |
Why?
| | Phosphorylation | 1 | 2009 | 1707 | 0.010 |
Why?
| | Time Factors | 2 | 2009 | 7123 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2010 | 1164 | 0.010 |
Why?
| | Cell Line | 2 | 2000 | 2823 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 2003 | 123 | 0.010 |
Why?
| | Clonal Anergy | 1 | 2003 | 52 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2017 | 2588 | 0.010 |
Why?
| | Staurosporine | 1 | 2000 | 22 | 0.010 |
Why?
| | Growth Substances | 1 | 2000 | 138 | 0.010 |
Why?
| | Autoantibodies | 1 | 2007 | 1509 | 0.010 |
Why?
| | fas Receptor | 1 | 2000 | 91 | 0.010 |
Why?
| | Etoposide | 1 | 2000 | 168 | 0.010 |
Why?
| | Membrane Potentials | 1 | 2000 | 278 | 0.010 |
Why?
| | Versicans | 1 | 1998 | 9 | 0.010 |
Why?
| | Hemagglutinins | 1 | 1998 | 10 | 0.010 |
Why?
| | Injections, Intraperitoneal | 1 | 1998 | 116 | 0.010 |
Why?
| | Nuclear Proteins | 1 | 2003 | 740 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 1998 | 138 | 0.010 |
Why?
| | Antigen-Presenting Cells | 1 | 1998 | 159 | 0.010 |
Why?
| | Transfection | 1 | 2000 | 926 | 0.010 |
Why?
| | Lymphoma | 1 | 1998 | 237 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1999 | 1041 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2003 | 1480 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 1998 | 892 | 0.010 |
Why?
| | Biomarkers, Tumor | 1 | 1998 | 1321 | 0.010 |
Why?
|
|
Dooms's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|